Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

evinacumab

regeneron headquarters

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

A phase 3 trial demonstrated a 31% reduction in the risk of death compared to chemotherapy

regeneron headquarters

Regeneron and CytomX partner to create conditional bispecific cancer therapies

CytomX is set to receive an upfront payment of $30m as well as milestones of up to $2bn

regeneron headquarters

Regeneron’s Libtayo combination granted FDA approval for non-small-cell lung cancer

The decision was based on superior survival outcomes of Libtayo plus chemotherapy

regeneron headquarters

Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review

The rare eye disease often impacts infants who are born before 31 weeks of pregnancy

- PMLiVE

Sanofi and Regeneron’s Dupixent approved by FDA for prurigo nodularis

The two phase 3 trials showed a meaningful reduction in itching

regeneron headquarters

Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

The results were shared at the European Society for Medical Oncology Congress 2022

regeneron headquarters

Regeneron’s Libtayo shows promising results in phase 2 skin cancer trial

In the phase 2 trial, 50.6% of patients achieved the primary endpoint of complete pathologic response

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12

There are currently no approved treatments for children with eosinophilic oesophagi under the age of 12

- PMLiVE

Sanofi and Regeneron receives FDA priority review for prurigo nodularis

Dupixent would be the first drug specifically indicated for the condition in the US

- PMLiVE

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Eligible patients will now be able to access the treatment through the NHS in England

- PMLiVE

Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Dupixent is the first and only drug specifically recommended for EoE in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links